HCW Biologics regained compliance with Nasdaq listing rules and completed a follow-on offering priced at $0.6055 per unit to raise approximately $1.5 million for clinical development of immunotherapies targeting chronic inflammation.
Lynch syndrome patients gain access to prevention vaccines in clinical trials, while immunotherapy advances depend on universal tumor testing for microsatellite instability. Cancer vaccines are moving from research to clinical reality.
A 24-year-old woman with refractory lupus achieved two successful pregnancies following dual-target CAR-T cell therapy, while bispecific T cell engagers showed efficacy in treatment-refractory antisynthetase syndrome and systemic sclerosis patients.